Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(28 sites)
Canada
Cross Cancer Institute, Edmonton, Alberta BCCA - Kelowna, Kelowna, British Columbia BCCA - Vancouver, Vancouver, British Columbia CancerCare Manitoba, Winnipeg, Manitoba The Moncton Hospital, Moncton, New Brunswick Regional Health Authority B, Zone 2, Saint John, New Brunswick Dr. H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador Royal Victoria Regional Health Centre, Barrie, Ontario William Osler Health System, Brampton, Ontario Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario Kingston Health Sciences Centre, Kingston, Ontario Waterloo Regional Health Network (WRHN), Kitchener, Ontario London Health Sciences Centre Research Inc., London, Ontario Stronach Regional Health Centre at Southlake, Newmarket, Ontario Lakeridge Health Oshawa, Oshawa, Ontario Ottawa Hospital Research Institute, Ottawa, Ontario Algoma District Cancer Program, Sault Ste. Marie, Ontario Niagara Health System, St. Catharines, Ontario St. Michael's Hospital, Toronto, Ontario St. Joseph's Health Centre, Toronto, Ontario Windsor Regional Cancer Centre, Windsor, Ontario CIUSSS de l'Est-de-I'lle-de-Montreal, Montreal, Quebec The Jewish General Hospital, Montreal, Quebec St. Mary's Hospital, Montreal, Quebec The Research Institute of the McGill University, Montreal, Quebec CHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Québec, Quebec Allan Blair Cancer Centre, Regina, Saskatchewan Saskatoon Cancer Centre, Saskatoon, Saskatchewan